SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Hull GW, Rabbani F, Abbas F, Wheeler TM, Kattan MW, Scardino PT. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol 2002; 167: 52834
  • 2
    Albertsen PC, Hanley JA, Gleason DF, Barry MJ. Competing risk analysis of men aged 55–74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 1998; 280: 97580
  • 3
    Patel HR, Mirsadraee S, Emberton M. The patient’s dilemma: prostate cancer treatment choices. J Urol 2003; 169: 82833
  • 4
    Gancarczyk KJ, Wu H, McLeod DG et al. Using the percentage of biopsy cores positive for cancer, pretreatment PSA, and highest biopsy Gleason sum to predict pathologic stage after radical prostatectomy: the Center for Prostate Disease Research nomograms. Urology 2003; 61: 58995
  • 5
    Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 2001; 58: 8438
  • 6
    Bostwick DG, Foster CS. Predictive factors in prostate cancer. current concepts from the 1999 College of American Pathologists Conference on Solid Tumor Prognostic Factors and the 1999 World Health Organization Second International Consultation on Prostate Cancer. Semin Urol Oncol 1999; 17: 22272
  • 7
    Cuzick J, Fisher G, Kattan MW et al. Long-term outcome among men with conservatively treated localised prostate cancer. Br J Cancer 2006; 95: 118694
  • 8
    Deshmukh N, Foster CS. Grading prostate cancer. In FosterCS, BostwickDG eds, Pathology of the Prostate. Chapt 11. Philadelphia: WB Saunders, 1997: 191227
  • 9
    Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 2005; 29: 122842
  • 10
    Partin AW, Kattan MW, Subong EN et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997; 277: 144551
  • 11
    D’Amico AV, Whittington R, Malkowicz SB et al. Combined modality staging of prostate carcinoma and its utility in predicting pathologic stage and postoperative prostate specific antigen failure. Urology 1997; 49 (Suppl.): 2330
  • 12
    Ohori M, Kattan MW, Koh H et al. Predicting the presence and side of extracapsular extension: a nomogram for staging prostate cancer. J Urol 2004; 171: 18449
  • 13
    Pisansky TM, Kahn MJ, Rasp GM, Cha SS, Haddock MG, Bostwick DG. A multiple prognostic index predictive of disease outcome after irradiation for clinically localized prostate carcinoma. Cancer 1997; 79: 33744
  • 14
    Egevad L, Granfors T, Karlberg L, Bergh A, Stattin P. Prognostic value of the Gleason score in prostate cancer. BJU Int 2002; 89: 53842
  • 15
    Andren O, Fall K, Franzen L, Andersson SO, Johansson JE, Rubin MA. How well does the Gleason score predict prostate cancer death? A 20-year followup of a population based cohort in Sweden. J Urol 2006; 175: 133740
  • 16
    Blute ML, Bergstralh EJ, Iocca A, Scherer B, Zincke H. Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. J Urol 2001; 165: 11925
  • 17
    Allsbrook WC Jr, Mangold KA, Johnson MH et al. Interobserver reproducibility of Gleason grading of prostatic carcinoma: urologic pathologists. Hum Pathol 2001; 32: 7480
  • 18
    Allsbrook WC Jr, Mangold KA, Johnson MH, Lane RB, Lane CG, Epstein JI. Interobserver reproducibility of Gleason grading of prostatic carcinoma: general pathologist. Hum Pathol 2001; 32: 818
  • 19
    Melia J, Moseley R, Ball RY et al. A UK-based investigation of inter- and intra-observer reproducibility of Gleason grading of prostatic biopsies. Histopathology 2006; 48: 64454
  • 20
    Amin MB, Grignon DJ, Humphrey P, Srigley JR. Gleason Grading of Prostate cancer: A Contemporary Approach Philadelphia PA: Lippincott, Williams & Wilkins 2004
  • 21
    Bostwick DG. Grading prostate cancer. Am J Clin Pathol 1994; 102 (Suppl. 1): S38S56
  • 22
    Egevad L. Reproducibility of Gleason grading of prostate cancer can be improved by the use of reference images. Urology 2001; 57: 2915
  • 23
    Albertsen PC, Hanley JA, Barrows GH et al. Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst 2005; 97: 124853
  • 24
    Berney DM. Low Gleason score prostatic adenocarcinomas are no longer viable entities. Histopathology 2007; 50: 68390